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founding; “adjusting” the results (whether
by stratification, conventional multiple re-
gression modeling, or regression modeling
of propensity scores) can never wholly re-
move the effect of confounding, although
adjustment would be expected to weaken
the effect estimates (ie, move the estimates
closer to no benefit). However, if patients
who received the apparently more benefi-
cial intervention had less favorable prog-
nostic characteristics, then the finding is
unlikely to be explained by confounding;
“adjusting” the results will still not wholly
remove the effect of confounding, but ad-
justment would be expected to strengthen
the effect estimates (ie, move the estimates
further away from no benefit).
RITA and RA grafts may be used to
revascularize different sites (circumflex or
right coronary) and in different ways (in
situ or pedicle grafts). In our observational
study, we recognized that grafts to the right
coronary artery are more prone to failure
and carefully controlled the analysis for
site of graft. However, we did not control
for the specific ways in which the conduits
were grafted. Whether one should do so
depends on the extent to which a surgeon’s
preferred grafting strategy is attributable to
the properties of the conduit being grafted.
We regard differences in the way that the
two conduits are grafted as aspects of the
overall strategies of using the RA or RITA
as arterial conduits.
The power of survival analyses is a
function of the number of events observed
(eg, deaths or cardiac-related events). The
number of events is increased both by the
number of subjects and the duration of fol-
low-up. Despite a median duration of fol-
low-up of only approximately 1.5 years in
the NRS,2 compared with 2.5 years in the
interim analysis of the RCT,1 the former
analysis of survival free from cardiac-re-
lated events had considerably more power.
It is not clear to us why using a com-
posite outcome should invalidate the find-
ings of the NRS or why Buxton and col-
leagues criticize this practice, because they
used it themselves (they reported cardiac
event-free survival and mortality alone, as
we did). In our study, the cardiac-related
“event” of recurrent angina was assigned
with reference to the findings of exercise
tolerance tests in exactly the same way for
both groups, thereby minimizing bias as far
as possible. Combining events hierarchi-
cally is the recognized way to analyze mul-
tiple events that may be attributable to the
underlying condition and that may be af-
fected by the interventions being com-
pared. This practice has been used in the
analysis of many internationally renowned
RCTs, for example, combining mortality
and nonfatal myocardial infarction4,5 and
mortality and heart failure.6 It is likely to
be important when mortality is rare, or
when mortality does not reflect outcomes
that are important to patients7; there is pre-
sumably no argument that recurrent angina
matters to patients. The issue of key impor-
tance is the avoidance of differential bias in
the assessment of events. Results are typi-
cally shown for events in a hierarchy of
severity, for example, actuarial survival and
cardiac event-free survival. Participants in a
study who die should not be censored or
omitted from analyses of cardiac event-free
survival, except in special circumstances.
There is a danger that research groups
become entrenched in their views about the
likely answer to a research question before
appropriate evidence becomes available.
We emphasize that this is not our position
and that we were careful in our criticism8
of the interim report of the RCT1 to restrict
our comments to technical points. It is per-
haps unfortunate that the two articles ap-
peared at a similar time. Before performing
our retrospective analysis, we had no prior
expectation that the RA would be better;
rather, we were concerned to ensure that
patients receiving RA grafts were not being
disadvantaged, as suggested by many other
researchers. We believe that our observa-
tional analysis suggests that using the RA
instead of the RITA may have benefits for
patients, and that the benefits may be large;
these are exactly the circumstances in
which the surgical community should col-
laborate to perform a definitive RCT.
Barnaby Reeves, PhD
Massimo Caputo, MD
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The excellent article written by Leyh and
colleagues motivated this letter.1 We hope
to share some of our extensive experience
with methylene blue (MB). It is important
to observe that Leyh and colleagues exam-
ined the results of MB therapy for norepi-
nephrine refractory vasoplegia “after car-
diopulmonary bypass (CPB),” although
this kind of situation may happen before
and even during CPB.
Our ongoing laboratory experiments
have proved the usual safe doses of MB in
regard to possible endothelium dysfunc-
tion. We have performed studies in porcine
arteries (coronary, renal, superior mesen-
teric, and hepatic), rabbit aortas, and canine
femoral arteries. By comparing sham ani-
mals with animals that received intrave-
nous (IV) MB, we found differences only
in intermediary concentrations in dose-re-
sponse curves to the calcium ionophore
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(A23187), which causes receptor-indepen-
dent nitric oxide release.
A single dose of IV MB (2 mg/kg, 20-
minute infusion time), as used by Leyh and
coworkers, was our first option in 1995.2
We are frequently asked about dose, infu-
sion, and route (venous or arterial). Many
colleagues tell us that they only observed a
transient effect using a 1 or 2 mg/kg IV
bolus. In our opinion, the IV MB bolus is a
rescue treatment. It is important to main-
tain a continuous infusion. In some cases,
we use a continuous infusion for more than
48 or 72 hours. Because the lethal doses of
MB are well known (40 mg/kg), it is pos-
sible to use higher doses if necessary. In
regard to the infusion route, in at least 1
anecdotal case, we observed a catastrophic
reaction to protamine without response to
norepinephrine or an IV MB bolus of 2
mg/kg. CPB was again established with
high flow, but we were unable to increase
the mean arterial pressure even with nor-
epinephrine infusion. The situation was
controlled only by using MB infusion in
the CPB arterial line again. Grayling and
Deakin3 presented this approach using MB
during CPB to treat valve endocarditis in a
case of ongoing septicemia.
In Argentina, Levin and colleagues4
performed a prospective, randomized study
including 638 patients who underwent car-
diac surgery, 56 (8.8%) of whom fulfilled
the vasoplegic postoperative criteria. The
overall mortality was 27 patients (4.2%), 6
(10.7%) of whom were in the vasoplegic
syndrome group and 21 (3.6%) of whom
were in the control group (P .02). The 56
patients with vasoplegic syndrome were
randomized to IV MB (1.5 mg/kg, 1-hour
infusion time) (28 patients) or placebo (28
patients). The general and surgical charac-
teristics of these 2 populations were quite
similar. There were no deaths in the MB
group and 6 deaths (21.4%) in the placebo
group. The MB resolution vasoplegia time
course was approximately 2 hours in all
cases. In those treated only with vasopres-
sors (8/28 patients, 28.6%), vasoplegia per-
sisted for more than 48 hours.
Since Gomes and colleagues5 described
vasoplegic syndrome, we speculate, as sur-
geons in undeveloped countries, whether
the vasoplegia was caused by some failure
in CPB material or drug quality control.
MB is increasingly used, for example in
liver transplantation. As there are few pa-
pers about its use in cardiac surgery it is
possible that cardiac surgical teams do not
consider vasoplegic syndrome to be a cat-
astrophic and unexpected problem, and it
may be underestimated.
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Reply to the Editor:
The results from the studies performed by
Evora and colleagues1,2 encouraged us to
use methylene blue (MB) as a rescue treat-
ment in catecholamine refractory vasople-
gia after cardiopulmonary bypass (CPB).3
We used an intravenous MB dose of 2
mg/kg as an infusion with a positive effect
in 92% of our patients. We selected this
dose because the majority of MB side ef-
fects obviously do not occur when a dose
of MB of 2 mg/kg or less is adminis-
tered.4-6 We have no experience with con-
tinuous MB infusion for more than 48
hours. Continuous MB infusion could be
an option for patients not responding to a
single dose of MB. However, more scien-
tific evidence is mandatory to define the
role of MB in the treatment of catechol-
amine refractory vasoplegia after CPB (eg,
multicenter, prospective, and randomized
studies). Even more important is a better
understanding of the mechanism triggering
vasoplegia after CPB to avoid this poten-
tially lethal complication, because a preop-
erative selection process to identify pa-
tients prone to vasoplegia after CPB could
result in prophylactic treatment with guan-
ylate cyclase inhibitors.
R. G. Leyh, MD
T. Kofidis, MD
M. Struber, MD
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